Assembly Biosciences Inc. (ASMB) 15.45 $ASMB
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), CLDN: 13.68 (-0.26), APS.TO: 7.70 (-0.09), PFBX: 9.33 (+0.12), VLTC: 11.54 (+0.50), APTO: 6.37 (-0.01), ALDX: 9.56 (-0.18), SNAK: 8.71 (-0.69), CLFD: 14.25 (+0.04), ASMB: 15.45 (-1.54), SGC: 19.02 (-0.08), ADTN: 15.98 (-0.03), CREE: 31.87 (-0.36)
Assembly Biosciences prices public offering of 5.556m common stock
M2 - Fri Mar 20, 4:59AM CDT
Biopharmaceutical company Assembly Biosciences (NasdaqCM:ASMB) disclosed on Thursday that it has priced its public offering of USD75m, or 5,555,555 shares of its common stock.
ASMB: 15.45 (-1.54)
Assembly Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 10:31AM CDT
ASMB: 15.45 (-1.54)
Assembly Biosciences Announces Pricing of $75 Million Public Offering of Its Common Stock
GlobeNewswire - Thu Mar 19, 7:37AM CDT
Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly"
announced today the pricing of an underwritten public offering of $75 million, or 5,555,555 shares of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a public offering price of $13.50 per share, before underwriting discounts. All of the shares in the offering are to be sold by Assembly. In addition, Assembly has granted the underwriters an option for a period of 30 days to purchase up to an additional 833,333 shares of common stock at the public offering price, less the underwriting discount.
ASMB: 15.45 (-1.54)
Assembly Biosciences to offer common stock in public offering
M2 - Thu Mar 19, 4:38AM CDT
Biopharmaceutical company Assembly Biosciences (NasdaqCM:ASMB) stated on Wednesday that it plans to start an underwritten public offering of its common stock.
ASMB: 15.45 (-1.54)
Assembly Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:12PM CDT
ASMB: 15.45 (-1.54)
Assembly Biosciences Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Mar 18, 3:01PM CDT
Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly" announced today that it is commencing an underwritten public offering of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission. All of the shares in the offering are to be sold by Assembly. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed.
ASMB: 15.45 (-1.54)
Assembly Biosciences (ASMB) in Focus: Stock Falls 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:31AM CST
Assembly Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day.
IPXL: 49.55 (-0.53), ASMB: 15.45 (-1.54)
Assembly Biosciences (ASMB) Looks Good: Stock Gains 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 8:25AM CST
Assembly Biosciences, Inc. (ASMB) was a big mover last session, with shares rising almost 8% on the day.
IPXL: 49.55 (-0.53), ASMB: 15.45 (-1.54)
Assembly Biosciences Announces Senior Management Changes
GlobeNewswire - Tue Feb 17, 6:58AM CST
Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced a number of senior management changes. Derek Small has been named Chief Executive Officer, in addition to his current position as President; current director William Ringo has been named non-executive Chairman; and David J. Barrett has been named Chief Operating Officer, in addition to his current role as Chief Financial Officer. As had been agreed during the merger establishing Assembly Biosciences last year, Mr. Small is succeeding Russell H. Ellison, MD, as CEO and Mr. Ringo is succeeding Dr. Ellison as Chairman. Dr. Ellison will continue to serve the company as a director until the 2015 annual meeting, and he will also continue as a Senior Advisor and head of Assembly's microbiome development program as the company approaches several key milestones.
ASMB: 15.45 (-1.54)
Diarrhea Therapeutic Pipeline Review H1 2015 Market Research Report - New at ReportsnReports.com
PRWeb - Sat Jan 31, 3:30AM CST
The report "Diarrhea - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for diarrhea. Diarrhea describes loose, watery stools that occur more repeatedly than usual. The most common cause of diarrhea is the stomach flu. Eating or drinking food or water that contains certain types of bacteria or parasites can also lead to diarrhea. Diarrhea and related complications can cause severe ill health. The most significant cause of severe ill health is loss of water and electrolytes. Signs and symptoms of diarrhea include dehydration, failure to thrive and malnutrition, abdominal pain, borborygmi and perianal erythema. Diarrheal disease may have a negative impact on both physical fitness and mental development. Complete Report is Available @ http://www.reportsnreports.com/reports/328713...-2015.html.
CBSTZ: 0.06 (unch), PFE: 35.27 (-0.09), ASMB: 15.45 (-1.54), PRTK: 28.87 (-0.31), NVS: 104.28 (-1.22)
Assembly Biosciences to Present at Investor Conferences
GlobeNewswire - Wed Dec 03, 7:10AM CST
Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in two investor conferences this week. The company has been invited to join a Hepatitis B Virus panel at the 26 Annual Piper Jaffray Healthcare Conference being held at The New York Palace in New York City. The panel is scheduled at 10:00am ET today and will be co-moderated by Piper Jaffray analysts Josh Schimmer, MD and Ted Tenthoff.
ASMB: 15.45 (-1.54)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 23.31 (-0.38), JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), ASMB: 15.45 (-1.54), GSK: 46.59 (+0.28), SVA: 5.10 (unch)
Infectitious Diarrhea - Pipeline Review, H2 2014
M2 - Mon Dec 01, 2:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wfb884/infectitious) has announced the addition of the "Infectitious Diarrhea - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Infectitious Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Infectitious Diarrhea and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Infectitious Diarrhea - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Infectitious Diarrhea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion - Assembly Biosciences - Cubist - Napo - Paratek - Pfizer - Prokarium - Shire - Summit For more information visit http://www.researchandmarkets.com/research/wf...fectitious
ASMB: 15.45 (-1.54)
Targacept Management Increases Urgency And Aims For Q4 Strategic Action
Daniel Ward - at Seeking Alpha - Fri Nov 07, 8:39AM CST
TRGT: 2.43 (+0.04), ASMB: 15.45 (-1.54), PRTK: 28.87 (-0.31)
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), CLDN: 13.68 (-0.26), APS.TO: 7.70 (-0.09), PFBX: 9.33 (+0.12), VLTC: 11.54 (+0.50), APTO: 6.37 (-0.01), ALDX: 9.56 (-0.18), SNAK: 8.71 (-0.69), CLFD: 14.25 (+0.04), ASMB: 15.45 (-1.54), SGC: 19.02 (-0.08), ADTN: 15.98 (-0.03), CREE: 31.87 (-0.36)
Assembly Biosciences prices public offering of 5.556m common stock
M2 - Fri Mar 20, 4:59AM CDT
Biopharmaceutical company Assembly Biosciences (NasdaqCM:ASMB) disclosed on Thursday that it has priced its public offering of USD75m, or 5,555,555 shares of its common stock.
ASMB: 15.45 (-1.54)
Assembly Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 10:31AM CDT
ASMB: 15.45 (-1.54)
Assembly Biosciences Announces Pricing of $75 Million Public Offering of Its Common Stock
GlobeNewswire - Thu Mar 19, 7:37AM CDT
Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly"
announced today the pricing of an underwritten public offering of $75 million, or 5,555,555 shares of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission at a public offering price of $13.50 per share, before underwriting discounts. All of the shares in the offering are to be sold by Assembly. In addition, Assembly has granted the underwriters an option for a period of 30 days to purchase up to an additional 833,333 shares of common stock at the public offering price, less the underwriting discount. ASMB: 15.45 (-1.54)
Assembly Biosciences to offer common stock in public offering
M2 - Thu Mar 19, 4:38AM CDT
Biopharmaceutical company Assembly Biosciences (NasdaqCM:ASMB) stated on Wednesday that it plans to start an underwritten public offering of its common stock.
ASMB: 15.45 (-1.54)
Assembly Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:12PM CDT
ASMB: 15.45 (-1.54)
Assembly Biosciences Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Mar 18, 3:01PM CDT
Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly"
announced today that it is commencing an underwritten public offering of its common stock pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission. All of the shares in the offering are to be sold by Assembly. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed. ASMB: 15.45 (-1.54)
Assembly Biosciences (ASMB) in Focus: Stock Falls 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:31AM CST
Assembly Biosciences saw a big move last session, as the company’s shares fell by over 7% on the day.
IPXL: 49.55 (-0.53), ASMB: 15.45 (-1.54)
Assembly Biosciences (ASMB) Looks Good: Stock Gains 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 8:25AM CST
Assembly Biosciences, Inc. (ASMB) was a big mover last session, with shares rising almost 8% on the day.
IPXL: 49.55 (-0.53), ASMB: 15.45 (-1.54)
Assembly Biosciences Announces Senior Management Changes
GlobeNewswire - Tue Feb 17, 6:58AM CST
Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced a number of senior management changes. Derek Small has been named Chief Executive Officer, in addition to his current position as President; current director William Ringo has been named non-executive Chairman; and David J. Barrett has been named Chief Operating Officer, in addition to his current role as Chief Financial Officer. As had been agreed during the merger establishing Assembly Biosciences last year, Mr. Small is succeeding Russell H. Ellison, MD, as CEO and Mr. Ringo is succeeding Dr. Ellison as Chairman. Dr. Ellison will continue to serve the company as a director until the 2015 annual meeting, and he will also continue as a Senior Advisor and head of Assembly's microbiome development program as the company approaches several key milestones.
ASMB: 15.45 (-1.54)
Diarrhea Therapeutic Pipeline Review H1 2015 Market Research Report - New at ReportsnReports.com
PRWeb - Sat Jan 31, 3:30AM CST
The report "Diarrhea - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for diarrhea. Diarrhea describes loose, watery stools that occur more repeatedly than usual. The most common cause of diarrhea is the stomach flu. Eating or drinking food or water that contains certain types of bacteria or parasites can also lead to diarrhea. Diarrhea and related complications can cause severe ill health. The most significant cause of severe ill health is loss of water and electrolytes. Signs and symptoms of diarrhea include dehydration, failure to thrive and malnutrition, abdominal pain, borborygmi and perianal erythema. Diarrheal disease may have a negative impact on both physical fitness and mental development. Complete Report is Available @ http://www.reportsnreports.com/reports/328713...-2015.html.
CBSTZ: 0.06 (unch), PFE: 35.27 (-0.09), ASMB: 15.45 (-1.54), PRTK: 28.87 (-0.31), NVS: 104.28 (-1.22)
Assembly Biosciences to Present at Investor Conferences
GlobeNewswire - Wed Dec 03, 7:10AM CST
Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in two investor conferences this week. The company has been invited to join a Hepatitis B Virus panel at the 26 Annual Piper Jaffray Healthcare Conference being held at The New York Palace in New York City. The panel is scheduled at 10:00am ET today and will be co-moderated by Piper Jaffray analysts Josh Schimmer, MD and Ted Tenthoff.
ASMB: 15.45 (-1.54)
Hepatitis B - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjfhp6/hepatitis_b) has announced the addition of the "Hepatitis B - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Abivax - AiCuris - Akshaya Bio - Alnylam - AlphaMab - AltraVax - Amarna Therapeutics B.V. - Arrowhead Research - Assembly Biosciences - Beijing Minhai Biotechnology - Benitec Biopharma Limited - Big DNA - BioDiem - Biological E. Limited - BioStar - Bolder Biotechnology - Bukwang Pharm - CEL-SCI - Celltrion - Chiasma - Chimerix - Chongqing Zhifei Biological Products. - ChronTech Pharma - Colby Pharmaceutical Company - Dynavax Technologies - F. Hoffmann-La Roche - GeneCure LLC - Genexine - Gilead Sciences - GlaxoSmithKline - GlobalAcorn - Green Cross - HEC Pharm. - Humabs BioMed - Ildong Pharmaceutical. - Immune Targeting Systems (ITS) - Immunovaccine - Inbiopro Solutions - Indian Immunologicals Limited - Isis - Johnson & Johnson - Leukocare - LG Life Sciences - Ligand - Mologen - Mucosis B.V. - NeuroVive Pharmaceutical - Novira Therapeutics - Panacea Biotec Limited - PharmaEssentia - REPLICor - RFS Pharma - Romark Laboratories - Sanofi Pasteur - Scynexis - Seek - Sinovac Biotech - SK Chemicals. - SomaGenics - Spring Bank - TCM Biotech - Tekmira - TetraLogic - Therametrics holding - THERAVECTYS - Transgene - Uni-Bio Science Group - Vaxart - Vaxine Pty - VLP Biotech - WaterStone For more information visit http://www.researchandmarkets.com/research/pj...epatitis_b
DVAX: 23.31 (-0.38), JNJ: 101.08 (+0.62), GILD: 103.69 (-1.52), ASMB: 15.45 (-1.54), GSK: 46.59 (+0.28), SVA: 5.10 (unch)
Infectitious Diarrhea - Pipeline Review, H2 2014
M2 - Mon Dec 01, 2:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wfb884/infectitious) has announced the addition of the "Infectitious Diarrhea - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Infectitious Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Infectitious Diarrhea and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Infectitious Diarrhea - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Infectitious Diarrhea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion - Assembly Biosciences - Cubist - Napo - Paratek - Pfizer - Prokarium - Shire - Summit For more information visit http://www.researchandmarkets.com/research/wf...fectitious
ASMB: 15.45 (-1.54)
Targacept Management Increases Urgency And Aims For Q4 Strategic Action
Daniel Ward - at Seeking Alpha - Fri Nov 07, 8:39AM CST
TRGT: 2.43 (+0.04), ASMB: 15.45 (-1.54), PRTK: 28.87 (-0.31)
